In a nutshell This phase 2 trial aims to test the effectiveness of a combined treatment with Brentuximab vedotin (Adcetris) in patients 60 years of age or more with Hodgkin lymphoma. The main outcome to be measured will be tumor response to the treatment and side effects. This trial is recruiting throughout the United States. The details...
Read MoreIn a nutshell This phase 3 trial aims to evaluate how effective pembrolizumab (Keytruda) is at treating triple negative breast cancer. The main outcome to be investigated is the invasive disease free survival. Other outcomes include the overall survival (time from treatment until death from any cause) and side effects. This trial is taking place...
Read MoreIn a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States. The details...
Read More
In a nutshell This study aimed to compare abemaciclib (Verzenio) to a placebo treatment (substance with no active effect). The study concluded that it increased progression-free survival and was relatively safe to use as a first-line treatment. Some background There are several treatment options for hormone positive, HER-2 negative...
Read More
In a nutshell This trial examined whether aggressive radiation would cause severe side effects in patients over 80 years old with early stage non-small-cell lung cancer (NSCLC). The authors concluded that SBRT is safe and tolerable for older patients. Some background Stereotactic body radiation therapy (SBRT) is a type of radiation that delivers...
Read More
In a nutshell This study examined whether practicing Tibetan yoga during chemotherapy can benefit sleep quality. This study concluded that practicing twice a week or more led to greater long-term benefits over time. Some background Sleep disturbances and fatigue are common side effects reported by patients undergoing chemotherapy. This can...
Read More
In a nutshell This study examined chemoradiation (CRT) + local excision (LE) treatment for stage I/II rectal cancer patients. The study found that CRT + LE was a suitable treatment for patients with higher risk stage I disease. Some background Rectal cancer is often treated with complete removal of the tumor and...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of merestinib in non-small cell lung cancer patients with a mutation in the MET protein. The primary outcome will be measured by the overall response to the treatment. This study is being conducted in Boston, Massachusetts. The details Merestinib is an inhibitor of the C-Met...
Read More
In a nutshell This phase 2 trial will clinical trial will test the effectiveness of lorlatinib in treating non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) mutations. The primary outcome will be measured by the rate at which the disease spreads to the central nervous system (CNS). The...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo), nivolumab with ipilimumab (Yervoy), or nivolumab with platinum-based chemotherapy compared with chemotherapy in treating patients with advanced non-small cell lung cancer (NSCLC). The primary outcome will be measured by the overall survival rate and time...
Read More
In a nutshell This phase 1 clinical trial will test the safety of isatuximab (SAR650984) in patients with relapsed or refractory multiple myeloma, as well as the effectiveness of isatuximab in multiple myeloma patients who have been previously treated with daratumumab (Darzalex). The primary outcome will be measured by side effects and overall...
Read More
